{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:23:55Z","timestamp":1790767435899,"version":"4.1.0"},"reference-count":23,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is the most common and cureless muscle pediatric genetic disease, which is caused by the lack or the drastically reduced expression of dystrophin. Experimental therapeutic approaches for DMD have been mainly focused in recent years on attempts to restore the expression of dystrophin. While significant progress was achieved, the therapeutic benefit of treated patients is still unsatisfactory. Efficiency in gene therapy for DMD is hampered not only by incompletely resolved technical issues, but likely also due to the progressive nature of DMD. It is indeed suspected that some of the secondary pathologies, which are evolving over time in DMD patients, are not fully corrected by the restoration of dystrophin expression. We recently identified perturbations of the mevalonate pathway and of cholesterol metabolism in DMD patients. Taking advantage of the mdx model for DMD, we then demonstrated that some of these perturbations are improved by treatment with the cholesterol-lowering drug, simvastatin. In the present investigation, we tested whether the combination of the restoration of dystrophin expression with simvastatin treatment could have an additive beneficial effect in the mdx model. We confirmed the positive effects of microdystrophin, and of simvastatin, when administrated separately, but detected no additive effect by their combination. Thus, the present study does not support an additive beneficial effect by combining dystrophin restoration with a metabolic normalization by simvastatin.<\/jats:p>","DOI":"10.3390\/ijms23042016","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T21:08:43Z","timestamp":1644786523000},"page":"2016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy"],"prefix":"10.3390","volume":"23","author":[{"given":"Nathalie","family":"Bourg","sequence":"first","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Vu Hong","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-1950","authenticated-orcid":false,"given":"William","family":"Lostal","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbass","family":"Jaber","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Guerchet","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Tanniou","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Bordier","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Bertil-Froidevaux","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Georger","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7985-2788","authenticated-orcid":false,"given":"Nathalie","family":"Daniele","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-446X","authenticated-orcid":false,"given":"Isabelle","family":"Richard","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-2195","authenticated-orcid":false,"given":"David","family":"Israeli","sequence":"additional","affiliation":[{"name":"G\u00e9n\u00e9thon, 91000 Evry, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000 Evry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1083\/jcb.122.4.809","article-title":"A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin","volume":"122","author":"Ervasti","year":"1993","journal-title":"J. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11940-014-0287-4","article-title":"Current Treatment and Management of Dystrophinopathies","volume":"16","author":"Goemans","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene Therapy for Duchenne Muscular Dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.spen.2021.100877","article-title":"Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New","volume":"37","author":"Mackenzie","year":"2021","journal-title":"Semin. Pediatr. Neurol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2004840117","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00424-021-02623-1","article-title":"Complexity of skeletal muscle degeneration: Multi-systems pathophysiology and organ crosstalk in dystrophinopathy","volume":"473","author":"Ohlendieck","year":"2021","journal-title":"Pflugers Arch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca 2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12864","DOI":"10.1073\/pnas.1509536112","article-title":"A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy","volume":"112","author":"Whitehead","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e14018","DOI":"10.14814\/phy2.14018","article-title":"Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy","volume":"7","author":"Kim","year":"2019","journal-title":"Physiol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Tarantino, N., Canfora, I., De Bellis, M., Musumeci, O., and Pierno, S. (2021). Molecular Sciences Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. Int. J. Mol. Sci, 22.","DOI":"10.3390\/ijms22042070"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13395-021-00276-3","article-title":"Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy","volume":"11","author":"Mucha","year":"2021","journal-title":"Skelet. Muscle"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3233\/JND-200524","article-title":"Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy","volume":"8","author":"Verhaart","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3233\/JND-219005","article-title":"Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020","volume":"8","author":"Whitehead","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcsm.12708","article-title":"Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy","volume":"12","author":"Amor","year":"2021","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Buscara, L., Gross, D.A., and Daniele, N. (2020). Of rAAV and men: From genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040258"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1083\/jcb.139.2.375","article-title":"Animal models for muscular dystrophy show different patterns of sarcolemmal disruption","volume":"139","author":"Straub","year":"1997","journal-title":"J. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/mt.2008.186","article-title":"Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2\/8 gene transfer","volume":"16","author":"Foster","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Servais","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JND-170288","article-title":"Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands","volume":"5","author":"Grounds","year":"2018","journal-title":"J. Neuromuscul. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:50Z","timestamp":1760134670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23042016"],"URL":"https:\/\/doi.org\/10.3390\/ijms23042016","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}